NEW YORK (GenomeWeb) – Exact Sciences today reported preliminary fourth quarter revenue of $14 million to $14.5 million, slightly below analyst estimates of $15.9 million. The company also said it expects full-year 2015 revenues of $39 million to $39.5 million.

Exact said it completed 38,000 Cologuard tests during Q4, and about 104,000 tests during the year — 2015 was the first full year of commercialization for the non-invasive colorectal cancer screening test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.